{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:45:37Z","timestamp":1791085537790,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T00:00:00Z","timestamp":1190851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T00:00:00Z","timestamp":1190851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/sj.leu.2404959","type":"journal-article","created":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T07:41:54Z","timestamp":1190878914000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo"],"prefix":"10.1038","volume":"22","author":[{"given":"M","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X H","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y K","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L W","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,27]]},"reference":[{"key":"BF2404959_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2005.10.980","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI . Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. J Clin Oncol 2005; 23: 657\u2013658.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hon.767","volume":"24","author":"F Bertoni","year":"2006","unstructured":"Bertoni F, Rinaldi A, Zucca E, Cavalli F . Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006; 24: 22\u201327.","journal-title":"Hematol Oncol"},{"key":"BF2404959_CR3","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES . Mantle-cell lymphoma. Semin Hematol 1999; 36: 115\u2013127.","journal-title":"Semin Hematol"},{"key":"BF2404959_CR4","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013\u20137023.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC . Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630\u2013639.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR7","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ . The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316\u20136325.","journal-title":"Clin Cancer Res"},{"key":"BF2404959_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349\u2013360.","journal-title":"Nat Rev Cancer"},{"key":"BF2404959_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676\u2013684.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667\u2013675.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105\u20132112.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR12","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","unstructured":"Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116\u2013121.","journal-title":"Ann Oncol"},{"key":"BF2404959_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705\u2013711.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR15","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927\u20131932.","journal-title":"Blood"},{"key":"BF2404959_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317\u2013324.","journal-title":"J Clin Oncol"},{"key":"BF2404959_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00063030-200620010-00002","volume":"20","author":"L Paoluzzi","year":"2006","unstructured":"Paoluzzi L, O\u2019Connor OA . Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006; 20: 13\u201323.","journal-title":"BioDrugs"},{"key":"BF2404959_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/sj.leu.2404511","volume":"21","author":"O Weigert","year":"2007","unstructured":"Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M . Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21: 524\u2013528.","journal-title":"Leukemia"},{"key":"BF2404959_CR19","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","volume":"109","author":"P Perez-Galan","year":"2007","unstructured":"Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D . The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441\u20134449.","journal-title":"Blood"},{"key":"BF2404959_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP . Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21: 333\u2013339.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"BF2404959_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","volume":"11","author":"JM Foran","year":"2000","unstructured":"Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11 (Suppl 1): 117\u2013121.","journal-title":"Ann Oncol"},{"key":"BF2404959_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257\u2013264.","journal-title":"Blood"},{"key":"BF2404959_CR23","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/sj.leu.2404797","volume":"21","author":"R Abou-Merhi","year":"2007","unstructured":"Abou-Merhi R, Khoriaty R, Arnoult D, El Hajj H, Dbouk H, Munier S et al. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV\/HHV-8-infected primary effusion lymphoma cells. Leukemia 2007; 21: 1792\u20131801.","journal-title":"Leukemia"},{"key":"BF2404959_CR24","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.M302559200","volume":"278","author":"YH Ling","year":"2003","unstructured":"Ling YH, Liebes L, Zou Y, Perez-Soler R . Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278: 33714\u201333723.","journal-title":"J Biol Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404959.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404959","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404959.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:51:54Z","timestamp":1648781514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["BF2404959"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404959","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,27]]},"assertion":[{"value":"5 April 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}